Supplementary Figure S5 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer

Figure S5 A, B. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 tumors harvested on day 16 post tumor inoculation. Number of cells per tumor mg are shown. (n=6 for esc1_Ctrl, n=8 for esc1_CCL5, representative data of two independent experiments.) C. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 DLN harvested on day 16 post tumor inoculation. (Left panel, n=12 for Ctrl, n=14 for esc1_CCL5, pooled data from two independent experiments. Right panel, n=18 for Ctrl, n=20 for esc1_CCL5. Pooled data from three independent experiments.) D, E. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 DLN harvested on day 16 post tumor inoculation. (n= 6 for Ctrl, n=8 for CCL5, representative data of two independent experiments.) F. Total cells (5*105cells/well) isolated from MOC1esc1_Ctrl or MOC1esc1_CCL5 DLNs were stimulated with indicated peptides for 48 hours and evaluated by IFN-γ ELISA. PC; (positive control (PMA + ionomycin)), NC; negative control (no peptides). (Left panel, n=8. Right panel, n=3, representative data of two independent experiments.) G. Flow cytometric analysis of MOC2_Ctrl and MOC2_CCL5 tumors harvested on day 10 post tumor inoculation. (n=8.)